Cancer

February 19, 2019

Combinatorial therapy for metastasis: A pharmacological mixture Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 20/February/2019, 12.54 am

Introduction: What they say: A study from Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA; Johns Hopkins Physical Sciences-Oncology Center, The Johns […]
February 19, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Paclitaxel (PTX) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 20/February/2019, `12.42 am

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells […]
February 19, 2019

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Fenofibrate and Paclitaxel(PTX) (FAP)  inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 20/February/2019, 12.23 am

Introduction: What they say:  A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on […]
February 19, 2019

Combinatorial therapy for prostate cancer:  A therapeutic mix encompassing  Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 20/February/2019, 12.09 am

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine […]